Wang Sicong has been banned!
On April 19, the microblog page of Wang Sicong, chairman of Beijing price capital and director of Wanda Group, showed that the user was currently in a state of silence due to violation of relevant laws and regulations.
Wang Sicong is banned
On April 19, Wang Sicong, a Weibo big V with more than 40 million fans, "chairman of Beijing price capital and director of Wanda Group", was banned.
The microblog page shows that the user is currently in a forbidden state due to violation of relevant laws and regulations.
Looking at Wang Sicong's microblog, his latest speech stayed on April 14. The page shows that Wang Sicong forwarded a video of "bedtime editorial department". The forwarded video is entitled "who recommended" Lianhua Qingwen, who told you? ", The owner said he "repeatedly questioned the efficacy and marketing model of Lianhua Qingwen".
According to the microblog editing records, Wang Sicong used the words "the CSRC should strictly investigate Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) " when forwarding the microblog for the first time, and then edited and deleted it.
Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) stop falling and turn up the dragon and tiger list display institutions sell in batches
Market data show that Wang Sicong's microblog did not have a significant impact on Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) share price on the day it came out. At the close of the day, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) even rose by the limit.
However, with the fermentation of public opinion, the next day, that is, April 15, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) opened sharply lower, opened and killed, fell to the limit for the first time after more than half an hour, and finally closed after more than two hours of "struggle". After a weekend, on April 18, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) opened straight down the limit. Today, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) opened with the limit, but opened the limit and pulled up. As of the close, the share price rose slightly by 0.06% to 32.41 yuan / share.
According to the after hours dragon and tiger list data, the four institutions sold a total of 305 million yuan, and Shenzhen Stock connect sold 399 million yuan and bought 177 million yuan.
On April 15, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) Secretary of the board of directors said in an interactive and easy to answer the questions of investors that "we believe that those who are clear will be clear about the untrue statements on the Internet, and will continue to track the development of the situation, and will safeguard their legitimate rights and interests through legal means when necessary".
Subsequently, on April 16, according to China Entrepreneur Magazine, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) responded positively to Wang Sicong's query. " Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) relevant person in charge" stated to "Chinese entrepreneur": "the company has never said on any occasion that 'who recommends Lianhua Qingwen'". "The above person in charge explained that what the who recognizes is the efficacy of traditional Chinese medicine including Lianhua Qingwen for covid-19 pneumonia."
According to the latest financial report data, in the first three quarters of 2021, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) achieved a revenue of 8.112 billion yuan, a year-on-year increase of 25.81%, and a net profit attributable to the parent company of 1.224 billion yuan, a year-on-year increase of 20.43%.
This year, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) share price continued to rise, up to 43.12 yuan / share, up to 120%.
